Malignant Ascites, Treatment Approach - Flowchart
Malignant Ascites, Treatment Approach - Flowchart Ascites Ascites
«Flowchart»

Patient with known malignant ascites

Patient with known malignant ascites

Patient with known malignant ascites

Female with malignant ascites probably/possibly due to ovarian cancer

Female with malignant ascites probably/possibly due to ovarian cancer

Female

Asymptomatic

Asymptomatic

Asymptomatic

Symptomatic

Symptomatic

Symptomatic

Treat as ovarian cancer with surgical debulking and chemotherapy. Use alternative methods if ascites uncontrolled.

Treat as ovarian cancer with surgical debulking and chemotherapy. Use alternative methods if ascites uncontrolled.

Treat as ovarian cancer with surgical debulking and chemotherapy. Use alternative methods if ascites uncontrolled.

Systemic therapy as appropriate

Systemic therapy as appropriate

Systemic therapy as appropriate

Hospice

Hospice

Hospice

End

End

End

Minimize intravenous hydration as much as possible (e.g., with chemotherapy)

Minimize intravenous hydration as much as possible (e.g., with chemotherapy)

Minimize intravenous

Limited/no systemic options, progressive disease

Limited/no systemic options, progressive disease

Limited/no systemic

Salt/free water restriction if possible
Diuresis with spironolactone ± furosemide as needed

Salt/free water restriction if possible
Diuresis with spironolactone ± furosemide as needed

Salt/free water restriction if possible
Diuresis with spironolactone ± furosemide as needed


Systemic therapy as indicated
Close monitoring with weights, physical examination

Systemic therapy as indicated
Close monitoring with weights, physical examination

Systemic therapy as indicated
Close monitoring with weights, physical examination


Percutaneous tunneled drainage catheter

Percutaneous tunneled drainage catheter

Percutaneous

Expected survival >3 mos
No loculation
Fluid nonviscous/bloody
No cardiac or renal dysfunction

Expected survival >3 mos
No loculation
Fluid nonviscous/bloody
No cardiac or renal dysfunction




Expected survival

Shunt

Shunt

Shunt

Systemic therapy as needed, repeat therapeutic paracentesis as needed

Systemic therapy as needed, repeat therapeutic paracentesis as needed

Systemic therapy as needed, repeat therapeutic paracentesis as needed

Consider intraperitoneal therapy if available or on clinical trial

Consider intraperitoneal therapy if available or on clinical trial

Consider intraperitoneal

Rapid recurrence of ascites with expected survival >4 weeks

Rapid recurrence of ascites with expected survival >4 weeks

Rapid recurrence

Progression of ascites or refractory to diuretics

Progression of ascites or refractory to diuretics

Progression of ascites or refractory to diuretics

Therapeutic paracentesis

Therapeutic paracentesis

Therapeutic paracentesis

Consider intraperitoneal therapy if available or on clinical trial

Consider intraperitoneal therapy if available or on clinical trial

Consider intraperitoneal

Trial of salt/free water restriction if possible
Diuresis with spironolactone ± furosemide as needed
Low threshold for declaring ineffective

Trial of salt/free water restriction if possible
Diuresis with spironolactone ± furosemide as needed
Low threshold for declaring ineffective



Trial of salt/free water

Transudative OR clearly due to increased portal pressure from extensive hepatic metastases or cirrhosis

Transudative OR clearly due to increased portal pressure from extensive hepatic metastases or cirrhosis

Transudative